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AutoimmuneThere are overwhelming data supporting the inﬂammatory origin of some epilepsies (e.g., Rasmussen's enceph-
alitis and limbic encephalitis). Inﬂammatory epilepsieswith an autoimmune component are characterized by au-
toantibodies againstmembrane-bound, intracellular or secreted proteins (e.g., voltage gated potassium channels).
Comparably, little is known regarding autoantibodies targeting nuclear antigen.We tested the hypothesis that in
addition to known epilepsy-related autoantigens, the human brain tissue and serum from patients with epilepsy
contain autoantibodies recognizing nuclear targets. We also determined the speciﬁc nuclear proteins acting as
autoantigen in patients with epilepsy.
Brain tissue sampleswere obtained frompatients undergoing brain resections to treat refractory seizures, from the
brain with arteriovenous malformations or from post-mortemmultiple sclerosis brain. Patients with epilepsy had
no known history of autoimmune disease and were not diagnosed with autoimmune epilepsy. Tissue was
processed for immunohistochemical staining. We also obtained subcellular fractions to extract intracellular IgGs.
After separating nuclear antibody–antigen complexes, the puriﬁed autoantigen was analyzed by mass spectrom-
etry.Western blots using autoantigen or total histones were probed to detect the presence of antinuclear antibod-
ies in the serum of patients with epilepsy. Additionally, HEp-2 assays and antinuclear antibody ELISAwere used to
detect the staining pattern and speciﬁc presence of antinuclear antibodies in the serum of patients with epilepsy.
Brain regions frompatientswith epilepsy characterized by blood–brain barrier disruption (visualized by extravasat-
ed albumin) contained extravasated IgGs. Intracellular antibodies were found in epilepsy (n = 13/13) but not in
multiple sclerosis brain (n = 4/4). In the brain from patients with epilepsy, neurons displayed higher levels of
nuclear IgGs compared to glia. IgG colocalizedwith extravasated albumin. All subcellular fractions from brain resec-
tions of patients with epilepsy contained extravasated IgGs (n = 10/10), but epileptogenic cortex, where seizures
originated from, displayed the highest levels of chromatin-bound IgGs. In the nuclear IgG pool, anti-histone autoan-
tibodies were identiﬁed by two independent immunodetection methods. HEp-2 assay and ELISA conﬁrmed the
presence of anti-histone (n = 5/8) and anti-chromatin antibodies in the serum from patients with epilepsy.
Wedeveloped amulti-step approach to unmask autoantigens in the brain and sera of patients with epilepsy. This
approach revealed antigen-bound antinuclear antibodies in neurons and free antinuclear IgGs in the serum of
patients with epilepsy. Conditions with blood–brain barrier disruption but not seizures, were characterized by
extravasated but not chromatin-bound IgGs. Our results show that the pool of intracellular IgG in the brain of
patients with epilepsy consists of nucleus-speciﬁc autoantibodies targeting chromatin and histones. Seizures
may be the trigger of neuronal uptake of antinuclear antibodies.
© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license. , Department of Cellular and Molecular Medicine, 9500 Euclid Ave., NB-20, Cleveland, OH 44195, USA. Fax: +1 216 444 9404.
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Studies on inﬂammatory mechanisms in epilepsy have been
burgeoning, with a 300% increase in published articles on PubMed
from 1993 to 2003 compared to the previous decade. It is thus not
surprising that new models of seizures have emerged. These models
take into account the knowledge gained from clinical studies, and are
based on mechanisms, receptors, and pathways that were formerly
reserved for the immunologist (Galanopoulou, 2013; Marchi et al.,
2007b, 2009; Vezzani et al., 2012). Evidence to support a role for inﬂam-
mation and autoimmunity in epilepsy has come from indirect and direct
sources. For example, the anticonvulsant activity of steroids in some
epilepsies (indirect (Marchi et al., 2011)), together with the presence
of inﬂammatory signs and markers in the serum or cerebrospinal ﬂuid
(CSF) of patients (direct (Nabbout, 2012)) have been interpreted as
clues suggestive of a role for the immune response. In addition, well-
established models of seizures which were developed to speciﬁcally
target neurons have been re-examined to reveal an underlying inﬂam-
matory etiology. For example, research has shown that a putative
muscarinic convulsant, pilocarpine, acts by immune activation and not
as previously suspected by a CNS exclusive action on muscarinic recep-
tors (Fabene et al., 2008; Marchi et al., 2007b, 2009; Uva et al., 2007).
The role of inﬂammation in seizure disorders has therefore been recog-
nized as an etiologic reality and as an important target for therapy
(Marchi et al., 2009, 2010, 2012b; Vezzani et al., 2011).
There are three groups of “inﬂammation-related seizures” (IRS): 1)
Seizures caused by the presence of a pathogen. These are perhaps the
least studied cluster of IRS and include seizures due to meningitis,
neurotropic pathogens, etc. In developing countries, pathogens are
considered the highest risk factor for acute seizure and increase the
risk of epilepsy by eleven fold (Bharucha et al., 2008). 2) A large family
of IRS encompasses autoimmune epilepsy syndromes, where one of the
etiological mechanisms is believed to be the presence of anti-neuronal
autoantibodies typically targeting either ion channels, intracellular epi-
topes or neurotransmitter receptors (Graus and Dalmau, 2012;
Lancaster and Dalmau, 2012;McKnight et al., 2005). 3) A number of sei-
zure disorders lacking either of these features (pathogen or autoanti-
bodies) can be classiﬁed as IRS based on a therapeutic response to
immunomodulators (Granata et al., 2008, 2011), vascular changes con-
sistent with an ongoing inﬂammatory process (e.g., blood–brain barrier
disruption; for a review see Janigro, 2012), or concomitant brain
changes that mimic some, but not all, signs of inﬂammation (Granata
et al., 2011; Nabbout, 2012; Nabbout et al., 2011).
As mentioned above, the third type of IRS may be linked to blood–
brain barrier (BBB) disruption. The BBB is the gatekeeper of immune
privilege in the CNS (Bechmann et al., 2007; Galea et al., 2007). The
BBB maintains ionic homeostasis which, in turn, controls neuronal
excitability (de Vries et al., 2012; Janigro, 2012; Marchi et al., 2012b;
Seiffert et al., 2004). Thus, BBB disruption (BBBD) not only causes loss
of immune privilege but may also directly result in seizures (Marchi
et al., 2007a). A reporter of BBB failure, extravasated albumin levels in
CSF, has also been used to detect focal BBBD by immunohistochemistry.
Interestingly, after diffusion through the CNS extracellular space, albu-
min accumulates in neurons and glia (David et al., 2009a,b; Seiffert
et al., 2004). Regions of focal BBBD can also be measured by detection
of extravasated IgGs. Whether extravasated IgGs also enter into the
brain cells it has not been fully elucidated (Michalak et al., 2012).
The presence of IgGs in the brain from patients with epilepsy,
together with our understanding of the pathophysiology of multiple
sclerosis (MS), has been used to propose autoimmunity as an etiologic
factor in seizure disorders. Autoantibodies to the NMDA, GABAB and
AMPA receptors, as well as the voltage-gated potassium channel and
its components LGI1 and CASPR2 have been detected in the CSF or
serum of patients with seizures (Lancaster and Dalmau, 2012). In addi-
tion, autoimmune diseases such as systemic lupus erythematosus (SLE)
greatly inﬂuence seizure susceptibility (Adelow et al., 2012). Thus,seizure threshold can be lowered by direct action on CNS targets
(e.g., glutamate receptors), by exposure to endotoxin (Galic et al.,
2008) or by autoimmune targeting of a speciﬁc antigen, such as nuclear
components. A recent paper has shown that even in the absence of au-
toimmune disease, IgG can be found in the brain of mice after lithium/
pilocarpine-induced seizures (Michalak et al., 2012). This is also consis-
tent with previous work showing that BBBD, as seen in regions of sei-
zure generation in the human brain, is characterized by large deposits
of extravasated IgG (Michalak et al., 2012). However, to date, the signif-
icance or consequences of IgG extravasation into the CNS has not been
fully elucidated.
The CNS of patients with epilepsy provides a unique environment
where the coupling of seizure with inﬂammation, loss of immune priv-
ilege and cell death may provide a mechanism for the generation and
uptake of autoantibodies against intracellular proteins. Therefore, we
examined whether or not autoantibodies against intracellular proteins
existed in the CNS and serum of patients with epilepsy where an auto-
immune or infectious etiologywas ruled out. By using a number of tech-
niques and an approach based on comparison of different pathologies
all characterized by BBBD, we isolated autoantigens from subcellular
fractions of the brain from patients with epilepsy. MS was used as a
comparative “neuro-autoimmune” disease, and brain resections
derived from cerebrovascular malformations as a means to study
BBBD independent of seizures. Our results demonstrate the presence
of antinuclear antibodies in the brain and serum from patients with
epilepsy, and the accumulation of autoantibodies in neuronal nuclei.
Materials and methods
The multimodal approach used for the experiments detailed in this
section is depicted graphically in Fig. 1.
Patient selection
Brain tissue specimens were obtained from patients conforming to
the guidelines of the Declaration of Helsinki. All patients signed an
informed consent according to institutional review protocols at the
Cleveland Clinic Foundation. Patient information and experimental use
of patient samples are summarized in Table 1. All brain tissue samples
were obtained from surgical resections with the exception of post-
mortem MS brain. Post-mortem samples were a generous gift of
Dr. Bruce Trapp's laboratory at the Cleveland Clinic Foundation Lerner
Research Institute. Inclusion criteria were willingness to participate to
the study and lack of positive diagnosis for an autoimmune disease.
One patient was identiﬁed as RA post-facto and is considered a positive
control (Fig. 6).
Detection and discovery
Immunohistochemical staining of brain tissue sections
The brain tissue was mounted using Tissue-Tek OCT compound
(Sakura Finetek Europe B.V., The Netherlands) and sectioned at approx-
imately 25 μm on a Leica CM3050 cryostat (Leica Microsystems Inc.,
Buffalo Grove, IL). Nine patients with epilepsy, 4 multiple sclerosis pa-
tients, and 3 arteriovenousmalformation (AVM) patientswere included
in these experiments.
Immunoﬂuorescent detection of IgG and albumin in neurons, glia and brain
parenchyma
Free-ﬂoating sections were stained for IgG and albumin. Non-
speciﬁc binding was minimized by incubation in a 3% goat serum
blocking solution at room temperature for 1 h. Sections of the brain tis-
sue were incubated with monoclonal mouse anti-human albumin anti-
body (1:1000; Sigma-Aldrich, St. Louis, MO). Fluorescently-labeled
secondary antibodies used were as follows: Alexa Fluor 594 polyclonal
donkey anti-mouse IgG (1:100; Jackson ImmunoResearch, West
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(1:200, Vector Labs, Burlingame, CA).
3,3′-Diaminobenzidine staining of AVM patient brain tissue
3,3′-Diaminobenzidine (DAB) staining of brain tissue sections was
achieved using the method from Marchi et al. (2010).
Immunoﬂuorescent detection of IgGs in neurons and astrocytes
Free-ﬂoating brain sections were stained for IgG and microtubule-
associated protein 2 (MAP2). Adjacent sections were stained for IgG
and glial ﬁbrillary acidic protein (GFAP). Non-speciﬁc binding was
minimized by incubation in a 3% goat serum blocking solution at room
temperature for 1 h. The following primary antibodies were used to
stain the tissue sections: mouse monoclonal anti-human MAP2
(1:1000; Covance, Princeton, New Jersey), mouse monoclonal anti-
human GFAP (1:500; Sigma-Aldrich, St. Louis, MO). The following sec-
ondary antibodies were used: goat anti-mouse polyclonal Alexa Fluor
594 (1:400, Jackson Immunoresearch, West Grove, PA), ﬂuorescein
goat polyclonal anti-human IgG (1:200; Vector Labs, Burlingame, CA).
Auto-ﬂuorescence was minimized using Sudan Black B. Finally, tissue
slices were placed on glass slides and mounted using a glass coverslip
and Vectorshield mounting medium containing 4′,6-diamidino-2-
phenylindole (DAPI) to visualize nuclei (Vector Labs, Burlingame,
CA). Images were obtained using a Leica Leitz ﬂuorescent microscope
and a Leica Microsystems upright confocal microscope with attached
cameras (Leica Microsystems, Allendale, New Jersey). Fluorescence in-
tensity and co-localization were measured using Q-Capture software
(Q-Capture, Surrey, BC, Canada). Three-dimensional reconstruction of
confocal images was performed using Velocity (PerkinElmer, Waltham,
Massachusetts).
Subcellular fractionation of brain tissue resections
Snap frozen tissue stored at−80 °C was processed according to the
protocol provided with the Thermo Scientiﬁc Subcellular Protein
Fractionation Kit for Tissue (Thermo Fisher Scientiﬁc, Rockford, IL).
200 mg of tissue was used for each fractionation. Ten patients with
epilepsy and 4 AVM patients were used for these experiments.
Western blots for IgG from subcellular fractions
Proteins from subcellular fractions were separated via SDS-PAGE
electrophoresis under non-denaturing conditions and transferred onto
a polyvinylidene diﬂuoride (PVDF) membrane (Millipore Corporation,
Billerica, MA). Membranes were incubated overnight at 4 °C with
horseradish peroxidase (HRP) conjugated anti-human IgG (1:2000;
Calbiochem-Novabiochem Corporation, CA, U.S.A.). Proteins were visu-
alized using Western Lightning Plus ECL (PerkinElmer, Waltham,
Massachusetts) and developed on Kodak Biomax MR Film (Eastman
Kodak Company, Rochester, New York). IgG volume was quantiﬁed
using Phoretix 2D software (Nonlinear USA Inc., Durham, North
Carolina).
Puriﬁcation and analysis
Indirect Immunoprecipitation
Nuclear fractions were divided into soluble nuclear and chromatin-
bound samples. Typically, indirect immunoprecipitation requires a
step to allow the antibody–antigen complex to form. However, as anti-
body–antigen complexes were already present in cell nuclei, no anti-
body–antigen complex forming step was required. Nuclear fractions
were incubated with protein-A coated agarose beads (Santa Cruz
Biotechnology Inc., Dallas, Texas) for 3 h at 4 °C with gentle mixing.
Beads were washed and centrifuged 4 times in 20% Tween–PBS to re-
move as much unbound protein as possible. Samples were then placed
in microcentrifuge tubes and exposed to a low pH (2.6) glycine–HCL
solution for 3, 15 or 30 min. After centrifugation and removal ofsupernatant (containing antigen), the pH of the supernatant was neu-
tralized with 1 M Tris at pH 8.5.
Liquid chromatography–mass spectrometry analysis
Antigen samples, obtained as described above, were analyzed by
SDS-PAGE electrophoresis. Bands were cut out of the gel, washed and
dehydrated in acetonitrile. Bands were reduced using dithiothreitol
and alkylated with iodoacetamide. Proteins were digested in gel over-
night at room temperature using 10 ng/μl trypsin in 50 mMammonium
bicarbonate. Proteins were extracted from the polyacrylamide with
acetonitrile (50%) and formic acid (5%). Extracts were evaporated in a
SpeedVac and resuspended in acetic acid (1%). Five microliter volumes
of extractwere injected on aDionex 15 cm × 75 μm idAcclaimPepmap
C18, 2 μm, 100 Å, reversed-phase capillary chromatography column for
liquid chromatography separation (Thermo Fisher Scientiﬁc Inc., Rock-
ford, IL). Peptides were eluted from the column by acetonitrile/formic
acid (0.1%) gradient at a ﬂow rate of 0.25 μl/min and introduced to the
mass spectrometry source on-line. For mass spectrometry analysis, a
Finnigan LTQ-Orbitrap Elite hybrid mass spectrometer system (Thermo
Fisher Scientiﬁc Inc., Rockford, IL) was used. The microelectrospray ion
source was operated at 2.5 kV. The peptide digest was analyzed using
the data-dependent multitask capability of the instrument acquiring
full scan mass spectra to determine peptide molecular weights and
ion spectra to determine the amino acid sequence.
Data from this experiment were analyzed using all collisionally-
induced dissociation spectra collected. These were used to search
the NCBI Mascot program with a human taxonomy ﬁlter. Manual in-
terpretation, Sequest and Blast were used to verify Mascot matches.
Identiﬁcation of potential antigens from mass spectrometry data
In our patient sample, time-dependent change in total antigen
content was evaluated. The procedure (see above) was used to study
both soluble nuclear and chromatin-bound fractions. Before collection,
columns were washed 4× to remove unbound proteins. Thus, the
remaining proteins were considered putative autoantigens; weakly-
bound non-speciﬁc IgGs were also present in this sample. Qualitative
analysis was achieved by examining the change in putative autoantigen
count observed over time. A positive increase in a given autoantigen
abundance (spectral count)was interpreted as elution of antigen tightly
bound to IgGs. In contrast, a negligible increase or decrease was
interpreted as non-speciﬁc binding of antigen to IgG. A transient
increase or decrease at 15 min followed by a return to levels less than
or equal to that observed at 3 min were not further analyzed. In short,
putative autoantigen were further analyzed only if they were not
obvious contaminants (e.g., keratins) and if their kinetic dissociation
was indicative of speciﬁc antibody–antigen binding.
An additional validation step was used to unveil autoantigen. We
compared the kinetics of soluble nuclear (presumably non-speciﬁc) vs.
chromatin-bound (speciﬁc) complexes. This analysis revealed that, in
the soluble nuclear fraction, the dissociation of protein from IgG was
not time-dependent. In fact, increase, decrease or no change in total
protein content were equally common. In contrast, the chromatin-
bound IgG–antigen dissociation was observed by a deﬁnite time-
dependent increase of dissociated autoantigen. The comparisons of
these two behaviors for each putative autoantigen (see Fig. 5) together
with the observations above were merged into the following:
30minCB–15minCBð Þ– 15minCB–3minCBð Þ½ 
– 30minSN–15minSNð Þ– 15minSN–3minSNð Þ½  ¼ Q
where Q is a coefﬁcient and where each value equals the normalized
spectral count of a given autoantigen. CB = chromatin bound fraction
and SN = soluble nuclear fraction. Q was used to discern between sol-
uble unbound IgG, and chromatin–IgG or histone–IgG complexes.
Fig. 1. Schematic representation of the experimental design used for different aspects of the research presented herein. The ﬁgure is divided in sections to highlight the three different
phases of this research effort. The phase labeled as Detection and discovery describes the process of isolation of brain samples from surgically resected specimens and their use to unveil,
by subcellular fractionation and immunohistochemical detection, antinuclear antibodies. The subcellular fractionation (see Fig. 4) allows segregating antigen–antibody complexes from
themembrane (M), cytoskeletal (CSk), cytosolic (Cy) and nuclear fractions. The nuclear fractionwas further divided into chromatin-bound (C) and soluble (S). At this stage, these fractions
were analyzed byWestern blotting with use of speciﬁc anti-human IgG antibodies. In parallel experiments, formalin-ﬁxed tissue was used to produce the results shown in Figs. 2 and 3.
Exogenous IgG antibodies (detection antibodies) were used to unveil endogenous IgG content in nuclear and subcellular fractions. After completion of these experiments a second phase
(Puriﬁcation and analysis) was undertaken. The ﬁrst step consisted of an indirect immunoprecipitation process where antigen–IgG complexeswere dissociated to obtain free antigen frac-
tions. These fractions were isolated from the brain; only soluble and chromatin-bound nuclear fractions were used. The antigens isolated by these means were further analyzed by mass
spec. to unveil (Identiﬁcation of antibody and antigen) the nature of IgG targets. These putative autoantigenswere divided into groups, endogenous histones or non-nuclear protein content.
To conﬁrm theseﬁndings, two separatemeans of investigationswere used. In theﬁrst step, brain-derived putative autoantigenswere probedbyWestern blotting to conﬁrmor refute their
suspected nature (histones, see Fig. 6). In addition, serum samples from patients with epilepsy and controls were isolated to conﬁrm the presence of antinuclear IgG in these samples.
Again, the speciﬁcities for histones of these antibodies were tested by Western blotting and also by an ad hoc ELISA. An additional set of non-epilepsy patient controls consisted of
using samples taken from the brain from patients withmultiple sclerosis (e.g., Figs. 2 and 3) or brain samples isolated during surgery to relieve arteriovenousmalformation (AVM) (Fig. 4).
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be likely autoantigen speciﬁcally bound to antibodies. Proteins were
then ranked from the most negative to least negative and any non-
nuclear proteins were eliminated. The nuclear proteins with the most
negative number were considered the primary targets of the autoanti-
bodies (Table 2).Identiﬁcation of antibody and antigen
Western blots using serum to detect isolated nuclear antigen
Protein from 1 patientwith epilepsy, serum from 8 patients with ep-
ilepsy, 2 control patients and 1 positive control patientwith rheumatoid
arthritis (RA) were used in this experiment. Isolated antigens from
the immunoprecipitation experiment were separated via SDS-PAGE
electrophoresis under non-denaturing conditions and transferred onto
a PVDF membrane. Membranes were incubated at room temperature
for 1 h with the serum from patients with epilepsy (1:1000). After re-
peated washing, membranes were incubated at room temperature for
2 h with HRP-conjugated goat anti-human IgG (1:2000; Calbiochem-
Novabiochem Corporation, CA, U.S.A.). Proteins were visualized using
Western Lightning Plus ECL and developed on Kodak Biomax MR Film.Western blots using serum to detect puriﬁed histones
Total histones were separated by SDS-PAGE electrophoresis under
non-denaturing conditions and transferred onto a PVDF membrane.
Membranes were incubated at room temperature for 1 h with the
serum from patients with epilepsy (1:500). After repeated washing,
membranes were incubated at room temperature for 2 h with HRP-
conjugated goat anti-human IgG (1:2000). Proteins were visualized
using Western Lightning Plus ECL and developed on Kodak Biomax
MR Film.
Anti-histone and anti-chromatin ELISA using serum
Serum obtained from human patients with epilepsy was diluted
1:300 in serum diluent (sterile ﬁltered 0.5% bovine gamma-globulin,
5% gelatin, 0.05 mM Tween in 1× PBS) and analyzed for levels of anti-
chromatin and anti-histone IgG autoantibodies. Microtiter plates
(Immulon 2HB) were coated with puriﬁed chromatin or total histones
overnight at 4 °C, blocked in 5% gelatin/PBS for 2 h, and incubated
with serum samples for 2 h. Secondary HRP-conjugated anti-human
IgG antibodies were added for 1.5 h and plates were developed using
10 mg/ml 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid)
(ABTS) in Mcllwain's buffer (0.09 M Na2HPO4, 0.06 M citric acid,
pH 4.6). Samples were read on a spectrophotometer at 405 nm.
Table 1
Patient
ID
Age Gender Seizures
Y/N
Epilepsy
Y/N
Diagnosis Etiology Pathology Autoimmune/
inﬂammatory
disease Y/N
Previous path./
surgery
Current AEDs Sample
type
Experimental
use
1 45 F Y Y Frontal lobe epilepsy Encephalomalacia Cortical atrophy and WM
degeneration
N Meningioma Carb, Lev Brain WB, IHC, IP, MS,
2 18 M Y Y Temporal lobe epilepsy Cortical malformation Neuronomegaly and loss of
cortical architecture
N Lam, Lev, Pheno, Clor Brain WB
3 2 m M Y Y Temporal lobe epilepsy Cortical malformation Cortical dysplasia, neuronal
cytomegaly/dysmorphia,
gliosis and microcalciﬁcations
N Lev, Lam, Oxcarb, Pheno Brain WB
4 23 M Y Y Temporal lobe epilepsy Hippocampal sclerosis Neuron loss and gliosis N Lam, Lev Brain WB, IHC
5 19 M Y Y Occipital lobe epilepsy Cortical malformation Cortical dysplasia N Vagus nerve
stimulator
Oxcarb, Clon Brain WB
6 1 M Y Y Temporal lobe epilepsy Hemimegalencephaly Cortical dysplasia, WM
atrophy and gliosis
N Vagus nerve
stimulator
Topi, Pheno Brain WB, IHC
7 12 F Y Y Frontal lobe epilepsy Cortical malformation Cortical dysplasia and gliosis N Val, Zon, Lev Brain WB, IHC
8A 14 M Y Y Temporal lobe epilepsy Cortical malformation,
encephalomalacia
w/porencephaly
Cortical dysplasia, ﬁbrotic
leptomeninges
N Topi, Lev, Clon Brain WB
8B 14 M N Y Temporal lobe epilepsy Cortical malformation,
encephalomalacia
w/porencephaly
Cortical dysplasia, ﬁbrotic
leptomeninges
N Topi, Lev, Clon Brain WB
9 7 M Y Y Parieto-occipital lobe
epilepsy
Ganglioglioma Ganglioglioma w/
cortical dysplasia
N Carb, Lev Brain WB, IHC
10 27 M Y Y Temporal lobe epilepsy Unknown Unknown N Unknown Unknown Brain IHC
11 46 F Y Y Temporal lobe epilepsy Unknown Unknown N Unknown Laco, Preg Brain IHC
12 48 M Y Y Temporal lobe epilepsy Unknown Unknown N Unknown Unknown Brain IHC
13 14 F Y Y Temporal lobe epilepsy Cortical malformation Cortical malformation N Carb, Pheny, Val,
Gabap, Lam, Pheno,
Top, Oxcarb, Lev
Brain IHC
14 36 M Y Y Temporal lobe epilepsy Cavernous angioma Cavernous angioma N Lev Serum WB-IP, WB-H,
ELISA, HEp-2
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15 29 F Y Y Temporal lobe epilepsy Unknown Unknown N Anterior temporal
lobectomy
(hippocampal sclerosis)
Carb Serum WB-IP, WB-H,
ELISA, HEp-2
16 32 M Y Y Temporal lobe epilepsy Unknown Unknown N Lam, Lev Serum WB-IP, WB-H,
ELISA, HEp-2
17 20 M Y Y Epilepsy Cortical malformation Perisylvian
polymicrogyria
N Vagus nerve stimulator Laco, Val Serum WB-IP, WB-H,
ELISA, HEp-2
18 21 F Y Y Temporal lobe epilepsy Unknown Unknown N Topi Serum ELISA, HEp-2
19 33 M Y Y Temporal lobe epilepsy Unknown Unknown N Lev Serum ELISA, HEp-2
20 30 F Y Y Temporal lobe epilepsy Unknown Unknown N Oxcarb, Clon Serum ELISA, HEp-2
21 38 M Y Y Temporal lobe epilepsy Unknown Unknown N Val Serum ELISA, HEp-2
22 Unknown Unknown N N Multiple sclerosisa Unknown Unknown Y Unknown Brain IHC
23 Unknown Unknown N N Multiple sclerosisa Unknown Unknown Y Unknown Brain IHC
24 Unknown Unknown N N Multiple sclerosisa Unknown Unknown Y Unknown Brain IHC
25 Unknown Unknown N N Multiple sclerosisa Unknown Unknown Y Unknown Brain IHC
26 48 M N N AVMw/ med. controlled
seizure
AVM N Embolization Val, Zon, Lev Brain WB, IHC
27 23 M N N AVMw/ no history
of seizure
AVM N Embolization Brain WB, IHC
28 37 F Y N AVMw/ epilepsy AVM N Embolization of the
left vertebral artery
Lev, Oxcarb, Pheny, Clon Brain WB, IHC
29 28 F N N AVM N Brain MRI
C1 26 M N N Healthy control N Serum ELISA, WB-IP,
WB-H, HEp-2
C2 33 M N N Healthy control N Serum ELISA, WB-IP,
WB-H, HEp-2
Pos. C 1 19 F Y Y Epilepsy Unknown Unknown Y (rheumatoid
arthritis)
Carb, Lam Serum WB-IP, ELISA, HEp-2
AED abbreviations: Carb = carbamazepine, Lev = levetiracetam, Lam = lamotrigine, Pheno = phenobarbital, Clor = clorazepate, Oxcarb = oxcarbazepine, Clon = clonazepam, Topi = topiramate, Val = valproate, Zon = zonisamide,
Pheny = Phenytoin, Laco = lacosamide, Preg = pregabalin,
Experimental use abbreviations: WB = Western blot, IHC = immunohistochemistry, IP = immunoprecipitation, MS = mass spectrometry, WB-IP = Western blot using immunoprecipitation samples, WB-H = Western blot using puriﬁed histones, ELISA =
enzyme linked immunosorbent assay, HEp-2 = human epithelial cell assay.
a Indicates post-mortem brain tissue samples. All other brain tissue specimens were obtained from surgical resections.
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Slides provided by the manufacturer (Bio-Rad, Hercules, CA) were
placed into a humidity chamber. Positive and negative controls provid-
ed with the manufacturers' kit were added (1:64 dilution) to two wells
of the slides in addition to 3 human serum controls and the serum from
8 patients with epilepsy (1:10 dilution). Slides were incubated for
20 min and then washed for 10 min in PBS. 25 μl of ﬂuorescein conju-
gate was added to each well of the slide and incubated in a humidity
chamber for 20 min. Images were obtained on a Leica Leitz ﬂuorescent
microscope with attached camera.
Results
For the results presented here we used a total of 32 subjects (includ-
ing control). 21 brain samples and blood from 11 donorswere analyzed.
Of the brain samples, 13 were obtained from patients affected bymulti-
ple drug resistant seizures, 4 were from patients treated by a neurosur-
geon to repair AVMs and 4 were post-mortem brain samples from
patients affected by MS. Brain samples were used for Western blotting,
immunohistochemistry and general morphology. Eight patients with
epilepsy, 2 healthy volunteers and 1 patient with epilepsy and RA
were enrolled to donate blood samples used for ELISA, HEp-2 andWest-
ern blot data. The AVM samples were obtained from 1 patient with sei-
zures responding to treatment, 1 patient with multiple drug resistant
seizures and 2 with no seizure history. None of the MS patients had a
history of epilepsy or seizures. Data obtained from the medical records
of patients used, including volunteers, are shown in Table 1.
Our experimental design also encompassed another layer of distri-
bution, namely the presence or absence of recurring seizures. Thus, 1
AVM patient where seizures were present at time of surgery was
grouped together with resected brain from patients with epilepsy
where focal electrophysiological properties (“spiking cortex”; see
Najm et al., 2006) were observed, while AVM patients with well-
controlled or no history of seizures were grouped with resections
from “non-spiking” areas of the brain from patients with epilepsy.
These criteria were only used for Fig. 4.
BBB disruption in multiple sclerosis, epilepsy, and AVM brain
One of the goals of this study was to detect and localize immunoglob-
ulins in the CNS.Weﬁrstwished to understand themechanisms bywhich
thesemacromolecular complexes gain entry into the brain. There are two
known mechanisms for IgG CNS ingress, namely passage across the BBB
or synthesis by CNS B lymphocytes (Ankeny and Popovich, 2010). Our re-
sults suggest that the former was the predominant source of CNS IgGs in
the brain from patients with epilepsy. Figs. 2A–B demonstrate the topo-
graphic overlap of extravasated immunoglobulins and albumin. Extrava-
sated IgGs and albumin were found in the extracellular as well as the
intracellular compartments (Figs. 2B1–B3). The arrows in B1–B3 points
to a neuron ﬁlled with IgGs and albumin.Table 2
Candidate autoantigens.
Protein CB-SN Accession
Histone H4 −2.83 4504301
Histone H2A type 1-C −2.07 4504245
Histone H2A type 1 −1.96 4504239
Histone H2B type 2-E −1.82 4504277
Histone H3.3 −0.92 4504279
Histone H1.3 −0.74 4885377
Histone H2A.Z −0.70 4504255
Core histone macro-H2A.1 isoform 2 −0.47 4758496
Heterogeneous nuclear ribonucleoproteins C1/C2 isoform a −0.18 11718997
Heterogeneous nuclear ribonucleoprotein A3 −0.16 34740329
Histone H1.0 −0.07 4885371
Nucleoside diphosphate kinase B isoform a −0.03 4505409
Autoimmune Association abbreviations: SLE = systemic lupus erythematosus.In the brain tissue from patients with epilepsy, gray matter neurons
were ﬁlled with IgGs (Fig. 2C1), while white matter extravasation of
IgGs was restricted to the extracellular space (Fig. 2C2). Note the con-
centric feature of IgG extravasation; a large venule (indicated by an as-
terisk) gave rise to a circular pattern of leakage. Two types of control
were used to conﬁrm or refute the hypothesis that the fate of extrava-
sated IgGs differs across pathologies. We used MS brain samples
(Figs. 2D1 and D2) as well as cortical samples isolated during repair of
AVM (Fig. 2E). In addition to differences between pathologies we also
detected topographic segregation of intracellular uptake patterns in
the brain from patients with epilepsy vs. MS brain (compare C and D).
Unlike in gray matter from patients with epilepsy (Fig. 2C1), MS brain
neuronal cell bodies were devoid of IgG content (Fig. 2D1). The arrows
in C1 indicate parenchymal cells while in C2 they indicate ectopic
neurons in white matter. In white matter of MS patients, extravasated
IgGs were found in the extracellular compartment; in contrast to what
was observed in neurons from patients with epilepsy, no nuclear IgGs
were present (asterisk in D2). The arrow in D2 points to a glial cell.
An additional “control” for the human brain with epilepsy and BBBD
is the use of resections obtained during AVM repair. Fig. 2E1 shows the
MRI of a typical AVM patient; the red arrow points to a region of extrav-
asated contrast agent (gadolinium). Themicrographs in Figs. 2E2 and E3
depict a pattern of IgG extravasation in a specimen obtained from an-
other AVMpatient. Note the lack of visible IgG accumulation in cell bod-
ies (asterisks in E2), as well as the gradient of IgG extravasation (shown
in E3). The dashed line indicates regions of maximum extravasation
while the dotted line in E3 refers to a broader region of extravasation
characterized by weak IgG signals. These results were conﬁrmed by
DAB-stained brain slices (Figs. 2E4 and E5) where variable extent of
IgG extravasation aswell as the absence of intracellular IgGwas evident
(enlargement in E4).
Detection and discovery
Fig. 3 shows a typical outcome of experiments where frozen sections
from the human brain with epilepsy or MS brain were stained for the
presence of neuronal or astrocyticmarkers aswell as for DNA. In brain tis-
sue resections from patients with epilepsy (Figs. 3A–B), intracellular and
nuclear staining of IgGwas readily revealed. However, intra-nuclear accu-
mulation of immunoglobulin was restricted to neurons while astrocytes
lacked intra-nuclear accumulation of IgGs despite robust uptake in the cy-
tosol (arrows in A1 and B1). The right side panels (Figs. 3A3–B2) show a
quantitative analysis of immunoﬂuorescence. A computer-drawn line
was used to detect the proﬁle of nuclear (blue) or immunoglobulin-
related (green) ﬂuorescence in different cells. These results show the
co-localization of IgG andDAPI in neurons (Fig. 3A3) but not in astrocytes
(Fig. 3B2). To further demonstrate the co-localization of DAPI with IgGs,
we used a three dimensional reconstruction of confocal images
(Fig. 3A2). Regardless of the methods used, the results demonstrate the
presence of ﬂuorescently labeled immunoglobulin in neuronal nuclei. In
comparison, although extravasation of IgG was widespread in MS brain,# Mass (kDa) Autoimmune Association Support
11 SLE Burlingame et al. (1994)
14 SLE Imaoka et al. (1990)
14 SLE Gu et al. (2013)
13
15 SLE Van Bavel et al. (2011)
22
13
39
5 33
39 SLE, scleroderma Siapka et al. (2007)
20
17
Fig. 2. Extravasation of IgGs in the brain of patientswith epilepsy coincideswith regions of albumin extravasation. A–B) Similar pattern of IgG and albumin extravasation. Themicrographs
show the presence of extravasated albumin and IgGs in tissue samples resected from the brain of a patient with epilepsy. Note that patterns of albumin and IgG extravasation around a
venule (A1 and A2) were virtually identical. Also note the intravascular presence of both albumin and IgG revealing the capillary network. B1–B3) Intracellular accumulation of albumin
differs from intracellular localization of IgGs. Note that unlike in the case of albumin, IgGs were detected not only in the extracellular space and in the cytosol but also in the nucleus of
neuronal cells (see also Fig. 3; arrows point to neuronal cell bodies). C–D)Different patterns of IgG homing in the brain frompatientswith epilepsy (C1–C2) compared tomultiple sclerosis
brain (D1–D2). In the case of the brain frompatientswith epilepsy, as indicated by the arrow in C1, IgG accumulationwasmostly restricted to neuronal cells. Large regions of extravasation
were seen around blood vessels as indicated by the dotted line in C2. The asterisk in C2 indicates the lumen of a large venule. The arrows point to cell bodies which, in regions of white
matter from the brain of patients with epilepsy, reveal cells with no intracellular accumulation of IgG in spite of the abundant presence of extracellular, extravasated immunoglobulin. In
the case of multiple sclerosis, as shown in D1 and D2, regions of extravasated IgGswere inversely correlated to graymatter extravasation patterns (D1 vs.D2). In addition, note that inMS
brain, cells identiﬁed as astrocytes revealed an uptake of IgGs in the cytosol but not in the nucleus (asterisk D2). E shows the same results in other tissue sections where DABwas used in
lieu of immunoﬂuorescence. Note the patchy proﬁle of IgG extravasation (E5) and the lack of intracellular staining in E4. In summary, while both epilepsy andMS brain reveal regions of
extravasated immunoglobulin, signiﬁcant differences were found when analyzing graymatter and ﬁber tracts. EPI-GM = graymatter of patient with epilepsy, EPI-WM = white matter
of patient with epilepsy, MS-GM = multiple sclerosis gray matter, MS-WM = multiple sclerosis gray matter.
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ﬁle lines in Fig. 3C2 show two continuous neurons to demonstrate the
lack of any IgG content in these cells.In order to determine the speciﬁc location of IgGs, subcellular
fractionation was performed. The Western blot in Fig. 4A shows
the presence of intracellular IgGs in each subcellular fraction. The
Fig. 3.Nuclear IgGs are exclusive to neurons in the brain of patients with epilepsy. These ﬁgures compare results obtained in the brain of patients with epilepsy (A–B) tomultiple sclerosis
tissue samples (C). The left panel shows the actual micrographswhile the right panel shows a schematic representation of the values of IgGs (in green) or nuclear DNA (in blue). Note that
in neurons, labeled by the neuronal marker MAP2, nuclear accumulation of IgGs was observed whereas in GFAP+ astrocytes from the brain of patients with epilepsy (B) the content of
intracellular IgGwas limited to the cytosol and 2 processes. Nuclear co-localization is also observed in a confocal 3D reconstruction (A2) of the brain tissue from a patientwith epilepsy. In
contrast, gray matter regions in MS brain (temporal lobe; C) revealed widespread extracellular leakage with neuronal cells (indicated by arrows) failed to reveal any signiﬁcant intracel-
lular accumulation of IgGs.
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responding to the heavy chain regions. Figs. 4B, C and D show the differ-
ence between pathologies with BBB leakage with no seizures vs. BBB
leakage in patients affected by seizures. AVM patients' brain displayed
abundant IgGs in soluble nuclear fractions but a less remarkable levelin the chromatin-bound fraction. In samples from patients with epilep-
sy, results demonstrated comparable amounts of IgGs in both soluble
nuclear and chromatin-bound fractions. In addition, the AVM patient
who also experienced seizures had similar levels of chromatin-bound
IgGs as patients with epilepsy (Figs. 4B, C and D patient #28). “Non-
Fig. 4. Subcellular fractionation and comparison of AVM and brain tissue from patients with epilepsy reveal that BBBD alone is not sufﬁcient to cause antibodies to bind to chromatin.
(A) Sub-fractioned brain of patients with epilepsy which was probed with HRP-conjugated anti-human IgG reveals abundant presence of immunoglobulin in all fractions tested. (B) No-
tably, chromatin-bound IgGs were quantitatively similar to levels in the soluble nuclear fraction of patients with epilepsy. Results were compared across several patients and against pa-
tients affected by AVM, a disease also characterized bywidespread leakage of the BBB (Manninger et al., 2005; Tu et al., 2006), revealing that the brain from patientswith epilepsy, but not
the brain from AVM patients, accumulates signiﬁcant amounts of IgGs in the chromatin-bound fraction. The bar graph in (C) shows the quantitative relationship betweenmeasured con-
tent in the 2 fractions based on pathology. The bar graph in (D) shows the same quantitative relationship between IgG in both fractions according towhether or not a patient had seizures.
Note that regardless of pathology, BBBD with seizure produces larger amounts of IgG bound to chromatin than with BBBD alone.
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IgG levels similar to those found in AVM patients without seizure
(Figs. 4B, C and D patient #8B).
Puriﬁcation and analysis
A secondmajor goal was to determine the molecular proﬁles of puta-
tive autoantigen in the nuclei of neurons frompatients with epilepsy. The
strategyused tounveil the nature of these autoantigens is described inde-
tail in the Materials and methods section. Fig. 5 summarizes the experi-
mental design and results. After disassociation of antigen from the
antibodies by low pH the soluble nuclear fraction displayed a dramatic
drop in protein content over time (Fig. 5A); this was the opposite of
what was observed in the chromatin-bound fraction where a dramatic
increase in protein content was observed (Fig. 5A). This was interpreted
as the presence of speciﬁc binding of IgG to nuclear proteins and chroma-
tin in comparison to free-ﬂoating or non-speciﬁcally bound protein–IgG
complexes in the soluble fraction. When mass spectrometry analysis
was performed, a number of non-nuclear proteins were found
and discarded (see Supplemental Table 1). When narrowing down
likely nuclear autoantigen candidates, themost prominent family of puta-
tive autoantigen was found in histones. The legend in Fig. 5B highlights
the molecular descriptions of the histones found to be signiﬁcantly asso-
ciated with speciﬁc binding to IgG in the chromatin fraction. All histones
tested behaved as predicted by the equation shown in the Materials and
methods section and according to the time-dependent association of
IgG and antigen shown in Fig. 5A. This also implies that IgG–histone bind-
ing displayed high afﬁnity owing to the fact that the kinetic proﬁle was
consistent with tight binding antibodies. This is in contrast to what wasobserved in the soluble fraction where histones were rapidly dissociated
from antibodies. A summary of themolecular properties and quantitative
analysis of histones and other putative autoantigens is shown in Table 2.
Identiﬁcation of antigen and antibody
While the results in Fig. 5 and Table 2 show an indirect approach to
determine the molecular nature of putative autoantigens found in the
brain frompatientswith epilepsy, these results heavily rely on statistical
analysis of mass spectrometry data. We performed three additional
immunodetection experiments to conﬁrm or disprove the presence of
histone-speciﬁc IgGs in patients with epilepsy. We ﬁrst used Western
blotting to qualitatively analyze histones by molecular weight. To this
end we prepared Western blots using protein extracts from the immu-
noprecipitation experiments shown in Fig. 5. In other words, we used a
mixture of nuclear protein that contained histones and other nuclear
proteins obtained from brain tissue resections of patients with epilepsy
as a target for patients' serum IgGs. In doing sowewished to test the hy-
pothesis that the putative autoantigens isolated from the brain were
also targets of IgGs present in the serum of patients with epilepsy. The
results are shown in Fig. 6A. Note that, when control serum was used,
no signiﬁcant immunosignal was detected, whereas with the serum
from patients with epilepsy a distinct band was apparent. This band
reﬂects the binding of IgGs isolated from the serum of patients with ep-
ilepsy to autoantigen isolated from IgGpresent inside cells of the human
brainwith epilepsy. This band also corresponds to themolecularweight
of histones (kDa). To conﬁrm that these bands indeed reﬂected the
presence of histones, we ran a similar gel (Fig. 6A; patient 17*) to
demonstrate that total histones are recognized by the same serum
Fig. 5.Mass spec. analysis reveals that histones are a likely target of autoantibodies in the brain from patients with epilepsy. (A) The average change in antigen concentration in a sample
obtained from the brain of a patient with epilepsy. After exposure to low pH, there is a dramatic decrease in protein concentration between 3 and 15 min with a moderate increase after
30 min in the soluble nuclear fraction. In the chromatin-bound fraction, there is a constant increase in protein concentration over time. These kinetic differences suggest the presence of
high afﬁnity antibodies in the chromatin-bound fraction and low afﬁnity antibodies (non-speciﬁc) in the soluble nuclear fraction. (B) When examining the dissociation kinetics for each
protein foundbymass spec., histonesmost closelymatched the average dissociation proﬁle seen in (A) suggesting that therewas speciﬁc binding of antibodies to histones in the chromatin
bound fraction. Refer to the legend for the dissociation kinetics of each histone observed. The inset at the top corresponds to the experimental steps in Fig. 1.
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target of IgG extracted from neuronal nuclei of brain tissue resections of
patients with epilepsy consists of histones.
While Western blots used to screen and conﬁrm the presence of
speciﬁc nuclear protein are useful for a few experiments, screening of
a larger number of subjects is less convenient. To this end we used
ELISA to quantitatively detect and quantify the presence of anti-
histone IgG (Fig. 6B). Note that in 5 of 8 patients with epilepsy a signal
suggestive of autoimmunity against histones was present. Also note
that in control subjects (labeled as C1) the signal was not present.
These results conﬁrm the Western blot ﬁndings shown in Fig. 6A but
also underscore the fact that these autoantibodies are not present in
all patients with epilepsy. However, some patients with epilepsy have
higher levels of antinuclear antibodies than the positive control
rheumatoid arthritis patient (labeled Pos. C 1).
The presence of anti-histone antibodies can be indicative of a
broader autoimmune response against multiple nuclear components.
That is, many antinuclear antibodies recognize not just histones, but
the histone–DNA complex (chromatin). Therefore, we tested the
hypothesis that in addition to anti-histone antibodies, the serum from
patients with epilepsy also contains autoantibodies targeting chromatin
(Fig. 6C). Using the HEp-2 assay, a distinct pattern of staining was dis-
covered. The serum from patients with epilepsy, but not the serum
from control subjects (Fig. 6C-C1) displayed various types of antinuclear
staining. The insets in the ﬁgures show speciﬁc binding to nuclei or
other sub-nuclear fractions (speciﬁcally nucleoli (Pt. 14) and centro-
meres (Pt. 16)). Note the similarity between the manufacturer's nega-
tive control and the serum control provided by the volunteer. The
HEp-2 assay results demonstrate that a clinical tool for the diagnosis
of autoimmune disease is able to detect the antinuclear antibodies in
the serum of patients with epilepsy.
Discussion
The main ﬁnding of this research is the presence of antinuclear anti-
bodies in the brain and serum from patients with epilepsy. These ﬁnd-
ings were obtained in patients who did not present any signs,
symptoms or clinical diagnoses of a typical autoimmune disease (such
as SLE). The serum from a patient with epilepsy also diagnosed withRA was used as a positive control to underscore that the levels of auto-
immune response in subjects with epilepsy were comparable to bona
ﬁde patients with autoimmune disease. Nuclear antibodies were pre-
dominately found in neurons and appeared to spare glia. Nuclear targets
included histones and chromatin. Autoimmune IgGs are derived from
the systemic circulation as their presence overlappedwith areas of albu-
min leakage across the BBB. An alternative interpretation may support
an indirect role of B lymphocytes in BBBD; this hypothesis needs to be
tested by ad hoc experiments.Signiﬁcance
Many clinical studies suggest that aberrations of the immune system
may be associated with seizures. Our results suggest the existence of a
new category of autoimmune epilepsy. Additionally, while a number
of studies have demonstrated the presence of antinuclear antibodies
in sera of patients with epilepsy, we have for the ﬁrst time shown that
these antibodies are able to enter the nuclei of neurons. We focused
on a population where antibodies against traditional “epilepsy related
autoantigen” were not present and discovered that the misguided
immune response in this population targeted the nuclear antigens
histones and chromatin. A previous report by others concluded that
subjects affected by epilepsy had levels of antinuclear antibodies similar
to non-epilepsy controls (Ranua et al., 2004). In these studies no
attempt was made to characterize these autoantigen as histones or
chromatin.When the studywas repeated in a controlled fashion, the au-
thors reported a signiﬁcant difference between prevalence of autoanti-
bodies in patients with epilepsy compared to control (Eriksson et al.,
2001; Peltola et al., 2000). Furthermore, these results were exclusively
based on the HEp-2 assay, which is qualitative, and not with a clinical-
grade ELISA test. In addition, the same group recently reported that an-
tinuclear antibodies are associated with recurrent seizures in patients
with refractory focal epilepsy (Peltola et al., 2000). Our results show a
convergence of positive ﬁndings, since both qualitative (HEp-2) and
quantitative tests (ELISA) demonstrated the presence of antinuclear
antibodies in patients with epilepsy. We also used an extracted nuclear
antigen fraction to conﬁrm the presence of IgG-bound autoantigen
which was found to be histones or chromatin.
Fig. 6. Amultimodal analysis of the serum from patients with epilepsy reveals the presence of speciﬁc anti-histone and anti-chromatin antibodies. (A) Immunoprecipitation isolated nu-
clear antigen taken from the brain tissue of a patient with epilepsy was ran on a gel and probed with the serum from patients with epilepsy and healthy controls. While control serum
produces no signal, the serum from patients with epilepsy produces a signal corresponding to histone complexes. Additionally, the serum from Pt. 26 was used to probe a gel containing
only puriﬁed histones (A-Pt. 17*). Note the similar binding pattern between both gels using the serum from patient 17. (B) ELISA quantifying anti-histone antibodies using the serum of
patients with epilepsy and control patients. The ELISA did not detect anti-histone antibodies in control serum but did detect them in 5 of 8 patients with epilepsy. Going further, a HEp-2
assay using the same serumdetected the presence of anti-chromatin antibodies (C). Patient 15 shows the speckled pattern of general antinuclear staining and patients 14 and 16 show the
speciﬁc binding pattern of anti-nucleolar and anti-centromere antibodies, respectively. The inset at the top of the ﬁgure refers to the phase of experimental design discussed in Fig. 1.
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albumin extravasation, we concluded that ingress of IgGs in neurons
occurred by a trans-endothelial route either across altered tight
junctions or by other trans-cellular means. We found no evidence
of local production of these immune molecules. Others also conﬁrm
the lack of signiﬁcant B cell presence in brain tissue resections of pa-
tients with epilepsy where an infectious trigger is not suspected
(Prayson and Frater, 2002).
In typical autoimmune epilepsy the presence of a pathogen is
often suspected but not always demonstrated (Nabbout, 2012).
Both bacterial and viral mechanisms have been proposed. The
onset and development of the autoimmune response may be due to
molecular mimicry or breaking of a barrier maintaining immunolog-
ical privilege. The latter is typical for CNS disorders owing to the
presence of a BBB. The question, however, remains of why an auto-
immune disease should cause seizures which are characterized by
neuronal hyperexcitability and synchronization, or alternatively do
seizures trigger an autoimmune disease? There are several lines ofevidence pointing to the devastating effect of antibodies targeting
ion channels (Lang et al., 2003), glutamate receptors, voltage gated
calcium and potassium channels, etc.(Graus and Dalmau, 2012;
Hoftberger et al., 2012). In these pathologies the proposed and ac-
cepted cascade of evidence/events is as follows: 1) The immune sys-
temmounts a response against a pathogen or against a self-molecule
perceived as such; 2) antibodies are produced to target these pro-
teins or a speciﬁc sequence; 3) upon binding to its target the anti-
body promotes loss of function or excessive function of one of the
several crucial components that regulate neuronal resting potential
or synaptic function (see Vincent et al., 2006 for details). We did
not directly investigate whether autoantibodies may have an inﬂu-
ence on and/or produce a downstream event that may impact
comorbidities such as cognitive decline. Antinuclear IgGs may be
yet another mechanism of seizure-induced neuronal cell loss origi-
nally described in hippocampal sclerosis but nowadays recognized
also for neocortical seizure disorders. However further experiments
are needed to determine the pathological mechanisms involves.
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How IgGs pass through a breached BBB is not known, nor is it under-
stood how once they enter the cellular compartment IgG may act as
“neurotoxins” (Levite andGanor, 2008). There aremany possiblemech-
anisms for their “toxic” actions, including cell-induced death by an im-
mune response, altered transcription owing to binding of IgGs to DNA,
altered mechanisms of cell cycle or apoptosis, etc. Our results show no
evidence of widespread neuronal cell death in the regions of albumin
and IgG extravasation. In fact, the cells displaying the most intra-
nuclear IgG content (for example Fig. 3A) were characterized by
healthy-appearing chromatin and nuclear content (Marchi et al.,
2004). Others have suggested that IgGs are “toxic” and that they pro-
mote neuronal cell death in the lithium/pilocarpine model of status
epilepticus or in the human cortex (Levite and Ganor, 2008; Michalak
et al., 2012).
Alternative hypotheses to speculate on the consequences of nuclear
IgGs in the human brain from patients with epilepsy may focus on
comorbidities rather than seizures themselves. It is well known that
complex sequelae of pathologies follow the onset and progression of ep-
ilepsy. This is particularly true for pediatric populationswhere develop-
mental delays, mental illness and other noxious consequences of
prolong seizures are often encountered. It is possible that given a similar
family history, seizure severity and age/gender patients deteriorate
more rapidly when neuronal cells are exposed to nuclear IgGs. It is
also possible, though it appears unlikely, that IgGs have a neuro-
protective effect.
A role for the blood–brain barrier?
Seizures are characterized bywidespreadvascular changes that span
from hyperemia to vascular leakage (Abe et al., 1997; Diehl et al., 1998;
Ivens et al., 2010; Janigro, 2012; Marchi et al., 2011, 2012a, 2013;
Weinand et al., 1997). We and others have shown that BBB disruption
precedes seizures in patients with epilepsy and that BBBD causes sei-
zures in humans and animals even in absence of a prior history of epi-
lepsy (for review see Marchi et al., 2012a). There is therefore strong
evidence that the BBB is impaired in patients with epilepsy, at least at
time of seizure onset. BBB leakage results in extravasation of IgGs
which is the ﬁrst step towards their ingress into the nuclear compart-
ment of neurons (Rigau et al., 2007). Thus, either BBBD, seizures, or
both may be necessary for this to happen. To address this hypothesis,
we performed experiments using two human pathologies also charac-
terized by BBB leakage but not seizures; we used post-mortem samples
of MS brain as well as brain samples isolated during surgeries to repair
AVM. We also studied samples from patients with BBBD and seizures
and compared those to BBBD but no ongoing seizures or negative
seizure history. To this end, in addition to resections of the brain from
patients with epilepsy, we used a “non-spiking” region of resected tem-
poral lobe (as a BBBD+ but no seizure) and AVM tissue from a patient
presenting with multiple drug resistant seizures (as BBBD+ and
seizure+) (see Table 1). The data in Fig. 4 show that chromatin-
bound autoantibodies were elevated in all samples from “spiking”
cortex, regardless of its origin. This group contained all tissue isolated
from foci of patients with epilepsy as well as AVM brain associated
with seizures. The group with the least chromatin-bound IgGs
encompassed brain samples from non-epilepsy patients and the brain
tissue resected from “non-spiking” brain of patients with epilepsy.
These preliminary results led us to conclude that leakage of the barrier
is necessary for entry of IgG into the parenchyma but is not sufﬁcient
to allow binding of antibodies to chromatin.
If BBB dysfunction is not sufﬁcient to cause accumulation of IgGs into
the nucleus of neurons, what is the likely mechanism? We propose a
scenario where seizures themselves are responsible for uptake of IgGs
into the nuclear compartment of neurons. According to this scenario,
prolonged excitation of neurons and other cellular elements occurringduring a seizure, and the subsequent metabolic mismatch, act synergis-
tically to decrease selective permeability of the cell membrane.
According to this hypothesis, a speciﬁc receptor is not necessary, but
rather, this uptake occurs due to a non-speciﬁc spreading depression-
like episode. However, this scenario explains how IgGs enter into the
cells but do not account for the presence in the nucleus. In fact, spreading
depression affects all cells in a certain region but nuclear uptake was
only present in neurons. How IgG may migrate from cytosol to nucleus
remains unknown. A recent paper has shown that electrical stimulation
characterized by low intensity (μA) and a frequency comparable to neu-
ronal ﬁring during an ictal event (50 Hz) causes translocation of
membrane-bound protein to the nucleus (Janigro et al., 2006). It is
thus possible that ﬁeld potential changes alone are sufﬁcient to cause
subcellular redistribution of macromolecules.
Potential pitfalls
One of the potential confounders in this study is the autoimmune
side-effects of certain anti-convulsants. For example, carbamazepine is
known to induce lupus-like symptoms or full-blown disease; this has
been shown to occur primarily in female patients (Schoonen et al.,
2010). This does not appear to be a signiﬁcant factor in our study be-
cause of all the patients enrolled, only 5 were under carbamazepine
therapy. In addition to carbamazepine, anecdotal reports have shown
that lamotrigine and valproate can produce lupus-like symptoms
(Bonnet et al., 2003; Chang and Cole, 2012). However, this was unlikely
to be a factor in antinuclear antibody generation in our patients as none
of them presented with symptoms of anti-convulsant drug-induced
lupus. The probability of ﬁnding antinuclear antibodies was, in other
words, unrelated to drug regimen. Others also found cohorts of patients
with epilepsy undergoing carbamazepine therapywith no symptoms or
signs suggestive of SLE (Ranua et al., 2004). It has to be noted, however,
that in this study the presence of antinuclear antibodies wasmore com-
mon in female patients compared to male. Of the three patients with
undetectable levels of auto-IgG, all were male while 60% of the patients
with detectable levels of anti-histone antibodies were female. This ﬁnd-
ing is in agreement with numerous ﬁndings linking autoimmune dis-
ease to gender differences (Danchenko et al., 2006).
Another possible limitation of this study is the fact that we did not
use CSF to test for autoantibodies. CSF analysis is a routine clinical ap-
proach to diagnosis infectious or autoimmune diseases. We did not
have access to CSF samples for the patient population whose data is
shown. Further experiments paired CSF and serum samples are being
performed to conﬁrm the diagnostic potential of antinuclear antibodies
in epilepsy.
Conclusions
Our results point to a sterile inﬂammation mechanism (Rock et al.,
2010) by which failure of the BBB promotes neuronal dysfunction. We
focused on three neurological conditions (epilepsy, multiple sclerosis,
AVM) all characterized by leakage of the BBB but found nucleus speciﬁc
IgGs only in the brain frompatientswith epilepsy andwithin these sam-
ples only in a population of neurons. IgGs directed towards histones and
chromatin were subsequently found in sera from other patients with
epilepsy suggesting that both compartments (circulatory and CNS) con-
tain these antibodies and that antibodies found in the serum are able to
bind nuclear protein extracted from brain sample of patients with epi-
lepsy. Thus, antinuclear autoantibodies may be a new mechanism of
seizure-induced neuronal death.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.nbd.2013.07.006.
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